Pharming will nominate Mr. Chouraqui for the appointment as Executive Director and Chief Executive Officer for a term of four years at an upcoming Extraordinary General Meeting of Shareholders (EGM).

Rare disease drug maker Pharming Group is calling off the search for a CEO successor to longtime chief Sijmen de Vries after landing on Fabrice Chouraqui. Chouraqui was most recently a CEO-partner at ...

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST ...

Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General ...

Leiden, the Netherlands, January 21, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces it will hold an Extraordinary General ...

Pharming has agreed a deal to sell a recently awarded priority review voucher (PRV) to Novartis for around $21 million - well below the market rate. The price of PRVs, which can be used to shorten ...

There is never a perfect time to do an interview, so carpe diem! It was a Monday morning; having managed to block the calendars of the Merchant family in Mumbai, I went up the thoroughfare to the ...

Pharming to nominate Fabrice Chouraqui as new executive director and chief executive officer: Leiden, the Netherlands Wednesday, January 22, 2025, 11:00 Hrs [IST] Pharming Group N ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...